Europe Branded Generics Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
USD
67.97 Billion
USD
96.49 Billion
2024
2032
 예측 기간 |
2025 –2032 |
 시장 규모(기준 연도) |
USD 67.97 Billion |
 시장 규모(예측 연도) |
USD 96.49 Billion |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
|
유럽 브랜드 제네릭 시장 세분화: 약물 종류별(항고혈압제, 호르몬제, 항대사제, 지질 저하제, 항간질제, 알킬화제, 항우울제, 항정신병제, 기타), 적용 분야별(심혈관 질환, 통증 관리 및 항염증제, 종양학, 당뇨병, 신경학, 위장 질환, 피부과, 기타), 투여 경로별(경구, 주사, 국소 투여, 기타), 제품 유형별(부가가치 브랜드 제네릭, 상품명 제네릭), 환자 인구 통계별(성인, 노인, 소아), 최종 사용자별(병원, 클리닉, 가정 간호, 학술 및 연구 기관, 기타), 유통 채널별(소매 약국, 병원 약국, 직접 입찰, 기타) - 산업 동향 및 2032년까지의 전망
유럽 브랜드 제네릭 시장 규모
- 유럽 브랜드 제네릭 의약품 시장은 2024년 679억 7천만 달러 규모였으며, 2032년에는 964억 9천만 달러 에 이를 것으로 예상됩니다.
- 2025년부터 2032년까지의 예측 기간 동안 시장은 연평균 4.5%의 성장률을 보일 것으로 예상되며, 이는 주로 의료비 지출 증가, 만성 질환 유병률 증가, 그리고 선진국 및 신흥 시장 모두에서 저렴하고 질 좋은 의약품에 대한 수요 증가에 힘입은 결과입니다.
- 이러한 성장은 오리지널 의약품의 특허 만료, 비용 효율적인 치료를 지원하는 정부 정책, 신흥 경제국의 의료 접근성 확대, 그리고 디지털 헬스 및 전자 약국 채널의 도입 증가에 힘입어 더욱 가속화되고 있습니다. 주요 제약 회사들의 지속적인 의약품 제형 혁신, 환자 순응도 향상 전략, 그리고 브랜드 제네릭 포트폴리오 확장은 전 세계 시장 확대를 더욱 촉진할 것으로 예상됩니다.
유럽 브랜드 제네릭 의약품 시장 분석
- 유럽 브랜드 제네릭 시장은 비용 효율적이고 고품질의 의약품에 대한 수요 증가에 힘입어 견조한 성장세를 보이고 있습니다. 이러한 제품은 제네릭 의약품의 경제성과 브랜드 인지도를 모두 갖추고 있습니다. 브랜드 제네릭은 환자의 복약 순응도를 향상시키고, 필수 의약품에 대한 접근성을 확대하며, 신흥 시장과 선진 시장 모두에서 제약 회사에 수익 창출 기회를 제공하는 데 중요한 역할을 합니다. 그러나 국가별 규제 차이, 가격 경쟁 심화, 그리고 브랜드 충성도 유지를 위한 지속적인 혁신의 필요성 등 여러 가지 과제에 직면해 있습니다.
- 만성 질환 관리, 종양학, 심혈관 질환 및 감염성 질환 치료 부문은 주요 성장 동력입니다. 비전염성 질환의 유병률 증가, 의료 인식 제고, 신흥 경제국의 의료 접근성 확대는 브랜드 제네릭 의약품에 대한 수요를 촉진하고 있습니다. 또한, 바이오시밀러와 특수 제네릭 의약품의 채택 증가는 효능과 안전성을 유지하면서 고가의 오리지널 의약품에 대한 대안을 제공함으로써 시장 역학을 변화시키고 있습니다. 제약 회사들은 브랜드 제네릭 의약품의 활용도를 높이기 위해 마케팅 전략, 환자 교육 및 전략적 파트너십을 활용하고 있습니다.
- 독일은 영국과 이탈리아의 지원을 받아 시장을 주도하고 있는데, 이는 잘 구축된 제네릭 의약품 제조 역량, 우호적인 정부 정책, 그리고 증가하는 의료비 지출 덕분입니다. 북미는 만성 질환 치료제에 대한 높은 수요, 확대되는 의료보험 적용 범위, 그리고 탄탄한 유통망에 힘입어 그 뒤를 따르고 있습니다. 유럽은 제네릭 의약품 대체 정책, 비용 절감 조치, 그리고 의료 효율성 향상에 대한 관심 증가에 힘입어 꾸준한 성장을 보이고 있습니다. 라틴 아메리카, 중동, 아프리카 등 신흥 시장은 의료 인프라 개선, 규제 완화, 그리고 제약 제조 역량 증대에 힘입어 점진적으로 제네릭 의약품을 도입하고 있습니다.
- 고혈압 치료제 부문은 편리한 복용법, 비용 효율성, 다양한 치료 분야에 적용 가능성에 대한 환자 선호도에 힘입어 22.51%의 시장 점유율로 시장을 주도할 것으로 예상됩니다.
보고서 범위 및 유럽 브랜드 제네릭 시장 세분화
|
속성 |
유럽 브랜드 제네릭 의약품 주요 시장 분석 |
|
포함되는 부문 |
|
|
대상 국가 |
유럽
|
|
주요 시장 참여자 |
|
|
시장 기회 |
|
|
부가가치 데이터 정보세트 |
데이터 브리지 마켓 리서치에서 제공하는 시장 보고서는 시장 가치, 성장률, 시장 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 체계에 대한 정보를 포함합니다. |
유럽 브랜드 제네릭 시장 동향
"합리적인 가격의 고품질 의약품에 대한 수요 증가가 유럽 브랜드 제네릭 시장 성장을 견인하고 있습니다."
- 의료비 상승, 고령화, 만성 질환 및 생활습관병의 증가로 유럽에서는 저렴하면서도 품질 좋은 의약품에 대한 수요가 증가하고 있으며, 이는 브랜드 제네릭 의약품의 성장을 뒷받침하고 있습니다. 브랜드 제네릭 의약품은 오리지널 의약품에 비해 비용 효율적인 대안을 제공하면서도 높은 효능과 안전성을 유지하고 있어 선진국 시장과 신흥 시장 모두에서 중요한 위치를 차지하고 있습니다.
- 정부와 의료비 지불기관들은 의료비 지출을 억제하고, 치료 접근성을 확대하며, 환자의 치료 순응도를 향상시키기 위해 정책, 상환 체계, 제네릭 대체 프로그램 등을 통해 브랜드 제네릭 의약품 사용을 적극적으로 장려하고 있습니다. 이러한 조치들은 심혈관 질환, 당뇨병, 종양학, 중추신경계 질환 등 다양한 치료 분야에서 시장 점유율 확대를 촉진하고 있습니다.
- 예를 들어, 2024년 3월 미국 FDA는 당뇨병 및 고혈압과 같이 수요가 높은 치료 분야에 대한 여러 신규 브랜드 제네릭 의약품을 승인했는데, 이는 브랜드 의약품에 대한 비용 효율적인 대안을 위한 파이프라인 활동 증가와 규제 지원 확대를 보여줍니다. 이는 환자와 의료 시스템의 요구에 부응하여 유럽 브랜드 제네릭 시장이 지속적으로 확장되고 있음을 나타냅니다.
- 신흥 경제국, 특히 독일과 라틴 아메리카에서는 의료 인프라 확충, 중산층 인구 증가, 그리고 치료 접근성 개선을 목표로 하는 정부 정책 덕분에 브랜드 제네릭 의약품의 사용이 빠르게 증가하고 있습니다. 기업들은 이러한 지역의 증가하는 수요를 충족하기 위해 현지 생산을 확대하고, 연구 개발에 투자하며, 유통망을 강화하고 있습니다.
- 유럽 의료 시스템이 경제성, 접근성 및 치료 순응도를 지속적으로 강조함에 따라, 브랜드 제네릭 의약품은 지속 가능한 의료 서비스 제공을 보장하는 동시에 제조, 포장 및 환자 중심의 의약품 개발 혁신을 주도하는 데 점점 더 중요한 역할을 하게 될 것입니다.
유럽 브랜드 제네릭 의약품 시장 동향
운전사
블록버스터급 의약품의 특허 만료
- 블록버스터급 의약품의 특허 만료 임박은 유럽 브랜드 제네릭 시장 확장의 가장 강력한 구조적 동인 중 하나입니다. 고수익 오리지널 의약품의 독점권이 만료되면 제네릭 및 바이오시밀러 제조업체가 경쟁력 있는 제품을 출시할 수 있는 길이 열리고, 이는 오리지널 의약품의 시장 점유율을 잠식하며 수요를 저렴한 대체 의약품으로 전환시킵니다.
- 이러한 "특허 절벽"은 연쇄적인 파급 효과를 촉발합니다. 제약회사들은 신약허가신청(ANDA)이나 바이오시밀러 신청을 서두르고, 규제 당국은 심사를 신속하게 처리하며, 보험사들은 제네릭 의약품을 점점 더 선호하고, 환자들은 더욱 저렴한 브랜드 제네릭 의약품을 이용할 수 있게 됩니다.
- 지난 10년간 주요 치료제에 대한 특허권 만료가 잇따르면서 기존 제네릭 업체와 신규 진입 업체 모두에게 기회가 반복적으로 생겨났고, 이는 가격 결정 구도를 바꾸고, 제네릭 의약품 제조 산업의 통합을 촉진하며, 신흥 시장으로의 지리적 확장을 가속화했습니다. 실제로 특허 만료로 인한 막대한 수익 규모는 복잡한 제네릭 의약품 및 바이오시밀러에 대한 투자를 정당화하는 경제적 근거가 되는 경우가 많습니다.
- 중요한 것은 특허 만료 시점의 예측 가능성 덕분에 제네릭 의약품 회사들이 전략적 계획을 세울 수 있는 기회를 얻을 수 있다는 점입니다. 이를 통해 회사들은 독점권 상실에 앞서 출시를 예측하고, 개발 파이프라인에 투자하고, 제휴를 맺고, 규제 당국에 사전 서류를 제출할 수 있습니다.
- 결과적으로, 브랜드 제네릭 의약품 부문은 블록버스터급 의약품 특허 만료와 밀접하게 연관된, 경쟁을 유발하는 순환적인 핵심 동력으로 자리매김하게 됩니다.
절제/도전
“특허 소송 및 지적 재산권 위험”
- 특허 소송 및 지적 재산권 위험은 유럽 브랜드 제네릭 의약품 시장에 상당한 제약 요인으로 작용합니다. 특허 분쟁의 복잡성과 장기화는 제네릭 의약품의 시장 진입을 지연시켜 시장 경쟁을 저해하고 약가 상승을 부추깁니다.
- 이러한 법적 분쟁에는 종종 사용 방법 특허 및 2차 특허를 포함한 여러 겹의 특허권 주장이 포함되며, 이는 브랜드 의약품의 독점 기간을 원래 특허 만료일 이후로 연장할 수 있습니다.
- 또한, 특허 침해 소송 방어에 드는 재정적 부담은 제네릭 의약품 제조업체, 특히 소규모 업체들이 시장 진입을 꺼리게 만드는 요인이 될 수 있습니다. 끊임없이 변화하는 특허법 환경과 오리지널 의약품 회사의 전략적 특허 포트폴리오 활용은 시장 역학을 더욱 복잡하게 만들어 전 세계적으로 브랜드 의약품과 제네릭 의약품이 공존하는 시장 구도를 형성할 가능성을 높입니다.
- 예를 들어, 2025년 10월, 이코노믹 타임스는 하이데라바드에 본사를 둔 나트코 파마가 척수근육위축증 치료제인 리스디플람과 관련하여 스위스 제약회사 로슈를 상대로 제기한 특허 분쟁에서 승소했다고 보도했습니다.
- 이러한 법적 및 재정적 장벽은 제조업체의 수익성과 환자의 저렴한 의약품 접근성 모두에 영향을 미칩니다. 전반적으로 특허 소송 및 지적 재산권 위험은 유럽 브랜드 제네릭 시장의 경쟁과 성장에 영향을 미치는 주요 제약 요인으로 남아 있습니다.
유럽 브랜드 제네릭 시장 범위
유럽 브랜드 제네릭 시장은 약물 종류, 적용 분야, 투여 경로, 제품 유형, 환자 인구 통계, 최종 사용자 및 유통 채널을 기준으로 7개의 주요 부문으로 세분화됩니다.
• 약물 종류별
유럽 브랜드 제네릭 시장은 약물 종류를 기준으로 항고혈압제, 호르몬제, 항대사제, 지질 저하제, 항간질제, 알킬화제, 항우울제, 항정신병제 및 기타로 세분화됩니다. 2025년에는 항고혈압제 부문이 22.51%의 시장 점유율로 시장을 주도할 것으로 예상되며, 이는 전 세계적으로 심혈관 질환 유병률이 증가하고 고혈압 관리에 대한 인식이 높아지고 환자와 의료진 모두 비용 효율적인 제네릭 의약품을 선호하는 경향이 커지고 있기 때문입니다.
고혈압 치료제 시장은 고정 용량 복합 요법의 지속적인 혁신, 저렴한 의약품 공급을 장려하는 정부 정책, 신흥 경제국의 의료 접근성 확대 등에 힘입어 2025년부터 2032년까지 연평균 7.0%의 성장률을 기록하며 성장세를 보일 것으로 예상됩니다. 이러한 요인들이 복합적으로 작용하여 고혈압 브랜드 제네릭 의약품의 소비를 촉진할 것으로 전망됩니다.
• 신청을 통해
적용 분야를 기준으로 시장은 심혈관 질환, 통증 관리 및 항염증, 종양학, 당뇨병, 신경학, 위장 질환, 피부과 및 기타 분야로 세분화됩니다. 2025년에는 심혈관 질환 분야가 29.30%의 시장 점유율로 시장을 주도할 것으로 예상됩니다. 이는 전 세계적으로 심장 관련 질환의 유병률이 증가하고, 고령 인구가 늘어나며, 예방적 심혈관 관리의 중요성이 부각되고, 비용 효율적인 브랜드 제네릭 의약품이 출시됨에 따라 더욱 가속화될 것으로 전망됩니다.
심혈관 질환 부문은 신흥 시장의 의료 시스템이 필수 의약품에 대한 접근성을 향상시키고, 고정 용량 복합 요법이 인기를 얻으며, 지속적인 연구 개발을 통해 심혈관 질환 치료용 브랜드 제네릭 의약품의 효능 및 안전성이 개선됨에 따라 연평균 5.9%의 꾸준한 성장세를 보일 것으로 예상됩니다.
• 투여 경로에 따라
투여 경로를 기준으로 유럽 브랜드 제네릭 의약품 시장은 경구, 주사, 국소 투여 및 기타로 구분됩니다. 2025년에는 경구 투여 부문이 55.87%의 시장 점유율로 시장을 주도할 것으로 예상되는데, 이는 경구 투여의 편리성, 높은 환자 순응도, 경구 제형의 광범위한 보급, 그리고 다른 투여 경로에 비해 비용 효율성이 높기 때문입니다.
경구용 의약품 시장은 만성 질환으로 인한 장기 투약 수요 증가, 자가 투여 치료법에 대한 선호도 상승, 그리고 생체 이용률이 향상되고 환자 친화적인 디자인을 갖춘 혁신적인 경구용 제제의 지속적인 출시 등에 힘입어 예측 기간 동안 4.7%의 가속화된 성장을 보일 것으로 예상됩니다.
• 제품 유형별
제품 유형을 기준으로 시장은 부가가치 브랜드 제네릭과 상표명 제네릭으로 구분됩니다. 2025년에는 부가가치 브랜드 제네릭 부문이 향상된 효능, 개선된 안전성, 환자 중심 제형, 그리고 표준 제네릭 대비 차별화된 치료 효과 제공 능력에 힘입어 66.87%의 시장 점유율로 시장을 주도할 것으로 예상됩니다.
부가가치가 높은 브랜드 제네릭 의약품 시장은 환자의 복약 순응도를 향상시키는 제형에 대한 의료 서비스 제공자의 선호도 증가, 병용 요법에 대한 수요 증가, 약물 전달 기술의 지속적인 혁신, 만성 및 복합 질환 치료에서 충족되지 않은 의료적 요구 해결에 대한 관심 증가에 힘입어 중요성이 커지고 있으며 연평균 4.6%의 성장률을 보이고 있습니다.
• 환자 인구 통계별
환자 인구 통계를 기준으로 시장은 성인, 노인 및 소아로 세분화됩니다. 2025년에는 성인 부문이 65.13%의 시장 점유율로 시장을 주도할 것으로 예상됩니다. 이는 성인 인구에서 심혈관 질환, 당뇨병, 고혈압과 같은 만성 및 생활 습관 관련 질환의 유병률이 높아 브랜드 제네릭 의약품에 대한 지속적인 수요를 견인하기 때문입니다.
성인 시장은 의료 서비스에 대한 인식 증가, 저렴한 의약품 접근성 향상, 신흥 경제국의 중산층 인구 증가, 그리고 성인 환자들 사이에서 효능과 복약 순응도가 더 우수한 부가가치 브랜드 제네릭 의약품에 대한 선호도 증가에 힘입어 연평균 4.6% 성장할 것으로 예상됩니다.
• 최종 사용자별
최종 사용자를 기준으로 시장은 병원, 진료소, 가정 간호, 학술 및 연구 기관, 기타로 세분화됩니다. 2025년에는 병원 부문이 51.52%의 시장 점유율로 시장을 주도할 것으로 예상됩니다. 이는 환자 치료 건수가 많고, 중환자 치료에 있어 브랜드 의약품과 고품질 제네릭 의약품에 대한 선호도가 높으며, 필수 의약품의 안정적인 공급을 보장하는 병원의 중앙 집중식 조달 방식 덕분입니다.
병원 부문은 병원 인프라 확장, 전문 병원 및 종합 병원 수 증가, 만성 및 급성 질환으로 인한 입원 환자 수 증가, 그리고 치료 결과 개선을 위한 입원 환자 치료에서의 부가가치 브랜드 제네릭 의약품 도입 증가에 힘입어 2025년부터 2032년까지 4.8%의 가장 빠른 성장률을 기록할 것으로 예상됩니다.
• 유통 채널별
유통 채널을 기준으로 시장은 소매 약국, 병원 약국, 직접 입찰 및 기타로 세분화됩니다. 2025년에는 소매 약국 부문이 52.52%의 시장 점유율로 시장을 주도할 것으로 예상됩니다. 이는 소매점을 통한 브랜드 제네릭 의약품의 광범위한 공급, 편리한 의약품 접근성에 대한 소비자 선호도, 그리고 도시 및 준도시 지역 모두에서 약국 체인과 독립 약국의 강력한 입지에 힘입은 결과입니다.
소매 약국 부문은 자가 치료 경향 증가, 비용 효율적인 브랜드 제네릭 의약품에 대한 인식 제고, 약국 네트워크 확장, 그리고 소매 채널을 통한 필수 의약품의 저렴한 접근성을 지원하는 정부 정책에 힘입어 2025년부터 2032년까지 4.7%의 가장 빠른 성장률을 기록할 것으로 예상됩니다.
유럽 브랜드 제네릭 의약품 시장 - 지역별 분석
- 독일은 저렴하면서도 고품질의 의약품에 대한 강력한 수요와 유럽 전역의 의료비 지출 증가에 힘입어 2025년 유럽 브랜드 제네릭 시장에서 18.75%의 최대 매출 점유율을 기록하며 선두 자리를 유지할 것으로 예상됩니다.
- 이러한 확장은 의료 인프라에 대한 정부 지원 증가, 만성 질환 유병률 증가, 치료 순응도에 대한 인식 제고 등 여러 요인에 힘입어 이루어지고 있으며, 이 모든 것이 브랜드 제네릭 의약품의 도입을 촉진하고 있습니다.
- 독일, 프랑스와 같은 국가들은 탄탄한 제약 제조 역량, 제네릭 의약품에 대한 규제 지원, 그리고 국내 의료 생산에 대한 투자 증가 덕분에 이 지역을 선도하고 있습니다.
- 또한, 국내 의약품 생산, 의료 접근성 및 의약품 수출을 장려하는 우호적인 정책들이 독일 시장 성장을 더욱 가속화하고 있습니다.
유럽 브랜드 제네릭 시장 분석
유럽은 잘 발달된 의료 시스템, 제네릭 의약품 대체 정책, 그리고 비용 절감에 대한 강조를 바탕으로 유럽 브랜드 제네릭 시장에서 중요한 위치를 차지하고 있습니다. 독일, 프랑스, 이탈리아, 영국과 같은 주요 경제국들은 높은 의료 접근성, 전문 제네릭 의약품의 도입 증가, 그리고 만성 질환 관리 투자 덕분에 시장을 선도하고 있습니다. 제네릭 의약품에 대한 규제 지원과 더불어 고령화 사회에 대한 관심 증가 및 저렴한 치료법에 대한 수요 증대가 시장 성장을 더욱 강화하고 있습니다. 제약 제조업체, 연구 기관, 그리고 의료 서비스 제공자 간의 지속적인 협력은 유럽 전역에 걸쳐 브랜드 제네릭 의약품의 지속적인 혁신과 효율적인 공급을 보장합니다.
프랑스 유럽 브랜드 제네릭 시장 분석
프랑스는 탄탄한 의료 인프라, 선진적인 제약 제조 역량, 그리고 국내 의약품 생산을 장려하는 정부 정책에 힘입어 유럽 브랜드 제네릭 시장에서 중요한 위치를 차지하고 있습니다. 만성 질환 관리, 종양학, 심혈관 질환 치료에 대한 프랑스의 집중적인 투자는 브랜드 제네릭 의약품에 대한 수요를 증가시키고 있습니다. 또한, 제약 회사와 연구 기관 간의 전략적 파트너십은 고부가가치 제네릭 의약품 및 전문 치료제 분야의 혁신을 촉진하고 있습니다. 의료 접근성, 경제성, 치료 순응도에 대한 프랑스의 지속적인 관심은 유럽 제약 시장에서 프랑스의 중요성을 더욱 강화하고 있습니다.
스페인 유럽 브랜드 제네릭 시장 분석
스페인은 의료 보장 확대, 합리적인 가격의 치료제에 대한 수요 증가, 만성 질환 관리 솔루션 도입 확대에 힘입어 유럽 브랜드 제네릭 의약품 시장에서 성장세를 보이고 있습니다. 스페인의 의료 시스템 현대화, 디지털 헬스케어 사업, 그리고 지역 제약 생산에 대한 집중적인 투자는 브랜드 제네릭 의약품의 사용을 가속화했습니다. 또한, 현지 제조업체, 연구 기관, 그리고 국제 제약 회사 간의 협력은 고품질 제네릭 제품의 혁신과 상용화를 뒷받침하고 있습니다. 스페인의 의료 인프라 투자와 환자 인식 개선 캠페인 역시 시장의 꾸준한 성장에 기여하고 있습니다.
독일 유럽 브랜드 제네릭 시장 분석
독일은 의료비 지출 증가, 제약 제조 산업의 급속한 발전, 만성 질환 및 생활습관병 유병률 증가에 힘입어 예측 기간 동안 가장 높은 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다. 인도, 중국, 일본과 같은 국가들은 국내 생산 능력 확대, 비용 효율적인 의약품 제조, 그리고 우호적인 규제 정책에 힘입어 성장을 주도하고 있습니다. 이 지역의 강력한 의약품 수출 역량, 의료 접근성 향상, 그리고 현지 의약품 생산을 위한 노력은 시장 성장을 더욱 가속화하고 있습니다. 치료 순응도에 대한 인식 제고와 고품질의 저렴한 의약품에 대한 수요 증가는 유럽 시장에서 이 지역의 지배력을 더욱 강화하고 있습니다.
해당 시장에서 활동하는 주요 시장 선도 기업은 다음과 같습니다.
- 테바 제약 주식회사(이스라엘)
- 비아트리스 주식회사(미국)
- 산도즈 그룹 AG(스위스)
- 닥터 레디스 래버러토리스(인도)
- 선 제약 산업 주식회사(인도)
- 아우로빈도 파마(인도)
- 시플라 제약(인도)
- 프레제니우스 카비(독일)
- 애보트(미국)
- Glenmark Pharmaceuticals(인도)
- 히크마 제약 주식회사(영국)
- 루핀 제약(인도)
- 엠큐어 제약(인도)
- 바우쉬 헬스 컴퍼니즈(캐나다)
- 맨카인드 파마(인도)
- 주빌런트 파마(인도)
- 나트코 파마(인도)
- 아리스토 파마슈티컬스 프라이빗 리미티드(인도)
- 바이오콘 리미티드(인도)
- 토렌트 제약 주식회사(인도)
- 엔도 주식회사(미국)
- 알렘빅 파마슈티컬스 리미티드(인도)
- SAGENT Pharmaceuticals (미국)
- 파나세아 바이오텍(인도)
유럽 브랜드 제네릭 시장의 최신 동향
- 2025년 10월, 미국 식품의약국(FDA)은 UZEDY(리스페리돈) 서방형 주사 현탁액의 적응증을 확대 승인했습니다. 이제 성인뿐만 아니라 13세에서 17세 사이의 소아 및 청소년 정신분열증 치료에도 사용이 승인되었습니다. 이는 만성 질환을 앓고 있는 젊은 환자들에게 장기적인 치료 옵션을 제공합니다.
- 2025년 8월, 테바는 미국 식품의약국(FDA)의 승인을 받아 삭센다(리라글루티드) 주사제의 첫 번째 제네릭 버전을 출시했습니다. 이 제네릭 GLP-1 수용체 작용제는 성인 및 소아 환자의 체중 관리 도구로 승인되어 만성 체중 관리에 더욱 접근하기 쉬운 선택지를 제공합니다.
- 2025년 8월, 비아트리스는 철분 결핍성 빈혈 치료제인 철분 수크로스 주사제의 첫 번째 제네릭 버전에 대해 미국 식품의약국(FDA)의 승인을 받았습니다. 이번 승인을 통해 미국 내 환자와 의료진은 보다 경제적인 치료 옵션을 이용할 수 있게 되었습니다. 또한, 이번 승인으로 비아트리스의 제네릭 주사제 포트폴리오가 강화되고, 환자들이 이 중요한 치료법을 더 쉽게 이용할 수 있게 되었습니다.
- 2025년 4월, 비아트리스는 일본 후생노동성에 범불안장애 치료제 에펙서(벤라팍신)의 추가 신약 허가 신청(Supplemental New Drug Application)을 제출했습니다. 이는 일본 시장에서 해당 약물의 치료 범위를 확대하기 위한 조치입니다. 승인될 경우, 일본에서 범불안장애를 앓고 있는 환자들에게 새로운 치료 선택지를 제공할 수 있을 것입니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE BRANDED GENERICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S FIVE FORCES ANALYSIS
4.2 BRAND OUTLOOK
4.2.1 PRODUCT VS BRAND OVERVIEW
4.2.1.1 PRODUCT OVERVIEW
4.2.1.2 BRAND OVERVIEW
4.3 CONSUMER BUYING BEHAVIOUR – EUROPE BRANDED GENERICS MARKET
4.4 INNOVATION TRACKER AND STRATEGIC ANALYSIS
4.4.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
4.4.1.1 JOINT VENTURES
4.4.1.2 MERGERS AND ACQUISITIONS
4.4.1.3 LICENSING AND PARTNERSHIP
4.4.1.4 TECHNOLOGY COLLABORATIONS
4.4.1.5 STRATEGIC DIVESTMENTS
4.4.2 NUMBER OF PRODUCTS IN DEVELOPMENT
4.4.3 STAGE OF DEVELOPMENT
4.4.4 TIMELINES AND MILESTONES
4.4.5 INNOVATION STRATEGIES AND METHODOLOGIES
4.4.6 RISK ASSESSMENT AND MITIGATION
4.4.7 FUTURE OUTLOOK
4.5 PATENT ANALYSIS – EUROPE BRANDED GENERICS MARKET
4.5.1 PATENT QUALITY AND STRENGTH
4.5.2 PATENT FAMILIES
4.5.3 LICENSING AND COLLABORATIONS
4.5.4 REGIONAL PATENT LANDSCAPE
4.5.5 IP STRATEGY AND MANAGEMENT
4.6 PRICING ANALYSIS
4.7 VALUE CHAIN ANALYSIS
4.7.1 OVERVIEW
4.7.2 RAW MATERIAL SUPPLY
4.7.3 COMPONENT MANUFACTURING AND PROCESSING
4.7.4 EQUIPMENT AND TECHNOLOGY PROVIDERS
4.7.5 DISTRIBUTION AND LOGISTICS
4.7.6 END-USERS (BRANDS & INDUSTRY SECTORS)
4.7.7 CONCLUSION
5 REGULATION COVERAGE
5.1 REGULATION COVERAGE (NORTH AMERICA)
5.2 REGULATION COVERAGE (SOUTH AMERICA)
5.3 REGULATION COVERAGE (EUROPE)
5.4 REGULATION COVERAGE (MIDDLE EAST & AFRICA)
5.5 REGULATION COVERAGE (ASIA-PACIFIC)
5.6 SUPPLY CHAIN ANALYSIS OF EUROPE BRANDED GENERICS MARKET
5.6.1 OVERVIEW
5.6.2 LOGISTIC COST SCENARIO
5.6.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS
5.6.4 CONCLUSION
5.7 TECHNOLOGICAL ADVANCEMENTS– EUROPE BRANDED GENERICS MARKET
5.7.1 ADVANCED FORMULATION TECHNOLOGIES
5.7.2 CONTINUOUS MANUFACTURING AND PROCESS OPTIMIZATION
5.7.3 ANTI-COUNTERFEITING AND SMART PACKAGING TECHNOLOGIES
5.7.4 MODIFIED DRUG DELIVERY SYSTEMS
5.7.5 DIGITAL TRANSFORMATION AND E-PRESCRIPTION INTEGRATION
5.7.6 ADVANCED ANALYTICAL AND QUALITY ASSURANCE TOOLS
5.7.7 PERSONALIZED GENERIC THERAPY DEVELOPMENT
5.7.8 SUSTAINABILITY AND ECO-FRIENDLY MANUFACTURING
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS
6.1.2 RISING PREVALENCE OF CHRONIC DISEASES
6.1.3 COST-EFFECTIVE ALTERNATIVE TO INNOVATOR DRUGS
6.1.4 SIMPLIFIED APPROVAL PATHWAYS FOR BRANDED GENERICS
6.2 RESTRAINS
6.2.1 PATENT LITIGATION AND INTELLECTUAL PROPERTY RISKS
6.2.2 COUNTERFEIT AND SUBSTANDARD DRUGS
6.3 OPPORTUNITIES
6.3.1 EXPANSION OF BRANDED GENERIC DRUG IN EMERGING MARKETS
6.3.2 PATENT CLIFF OF MAJOR DRUGS
6.3.3 EXPANSION INTO SPECIALTY AND COMPLEX GENERICS
6.4 CHALLENGES
6.4.1 INTENSE PRICE PRESSURE AMONG COMPETITORS
6.4.2 QUALITY PERCEPTION & PHYSICIAN/PATIENT TRUST IN BRANDED GENERIC DRUG
7 EUROPE BRANDED GENERIC MARKET, BY DRUG CLASS
7.1 OVERVIEW
7.2 ANTI-HYPERTENSIVE
7.2.1 DIURETICS
7.2.2 CE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS)
7.2.3 ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS)
7.2.4 BETA BLOCKERS (BBS)
7.2.5 CALCIUM CHANNEL BLOCKERS (CCBS)
7.2.6 DIRECT VASODILATORS
7.2.7 ALPHA-1 BLOCKERS
7.2.8 CENTRAL ALPHA-2 AGONISTS
7.2.9 HORMONES
7.2.10 STEROID HORMONES
7.2.11 SEX HORMONES
7.2.12 ESTROGENS
7.2.13 PROGESTOGENS
7.2.14 ANDROGENS
7.2.15 THYROID HORMONES
7.2.16 OTHER HORMONES
7.3 ANTIMETABOLITES
7.3.1 PURINE ANALOGUES
7.3.2 PYRIMIDINE ANALOGUES
7.3.3 FOLATE ANTAGONISTS
7.4 LIPID LOWERING DRUGS
7.4.1 STATINS (HMG-COA REDUCTASE INHIBITORS)
7.4.2 COMBINATION PRODUCTS AND OTHER AGENTS
7.4.3 FIBRATES
7.4.4 BILE ACID SEQUESTRANTS
7.4.5 PCSK9 INHIBITORS
7.5 ANTI-EPILEPTICS
7.6 ALKYLATING AGENTS
7.6.1 NITROGEN MUSTARDS
7.6.2 NITROSOUREAS
7.6.3 ALKYL SULFONATES
7.6.4 TRIAZENES
7.6.5 ETHYLENIMINES
7.7 ANTI-DEPRESSANTS
7.7.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
7.7.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
7.7.3 TRICYCLIC ANTIDEPRESSANTS (TCAS)
7.7.4 ATYPICAL ANTIDEPRESSANTS
7.7.5 MONOAMINE OXIDASE INHIBITORS (MAOIS)
7.7.6 NMDA RECEPTOR ANTAGONISTS
7.8 ANTI-PSYCHOTICS
7.8.1 SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS
7.8.2 FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS
7.8.3 PHENOTHIAZINES
7.8.4 THIOXANTHENES
7.8.5 NEXT-GENERATION ANTIPSYCHOTICS
7.9 OTHERS
8 EUROPE BRANDED GENERICS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 CARDIOVASCULAR DISEASES
8.3 PAIN MANAGEMENT AND ANTI-INFLAMMATORY
8.4 ONCOLOGY
8.5 DIABETES
8.6 NEUROLOGY
8.7 GASTROINTESTINAL DISEASES
8.8 DERMATOLOGY
8.9 OTHERS
9 EUROPE BRANDED GENERIC MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.3 INJECTABLEA
9.4 TOPICAL ADMINISTRATION
9.5 OTHERS
10 EUROPE BRANDED GENERICS MARKET, BY PRODUCT TYPE
10.1 OVERVIEW
10.2 VALUE-ADDED BRANDED GENERICS
10.3 TRADE NAMED GENERICS
11 EUROPE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS
11.1 OVERVIEW
11.2 ADULT
11.3 GERIATRIC
11.4 PEDIATRIC
12 EUROPE BRANDED GENERICS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 CLINICS
12.4 HOMECARE
12.5 ACADEMIC & RESEARCH INSTITUTES
12.6 OTHERS
13 EUROPE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 RETAIL PHARMACIES
13.3 HOSPITAL PHARMACIES
13.4 DIRECT TENDERS
13.5 OTHERS
14 EUROPE SHIP REPAIR AND MAINTENANCE SERVICES MARKET, BY REGION
14.1 EUROPE
14.1.1 GERMANY
14.1.2 UNITED KINGDOM
14.1.3 ITALY
14.1.4 FRANCE
14.1.5 SPAIN
14.1.6 TURKEY
14.1.7 RUSSIA
14.1.8 SWITZERLAND
14.1.9 NETHERLANDS
14.1.10 BELGIUM
14.1.11 SWEDEN
14.1.12 DENMARK
14.1.13 NORWAY
14.1.14 FINLAND
14.1.15 REST OF EUROPE
15 EUROPE BRANDED GENERICS MARKET: COMPANY LANDSCAPE
15.1 MANUFACTURER COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 VIATRIS INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 SANDOZ GROUP AG
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 DR.REDDY’S LABORATORIES LTD.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 ALEMBIC PHARMACEUTICALS LIMITED
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 AMNEAL PHARMACEUTICALS LLC.
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 ARISTO PHARMACEUTICALS PRIVATE LIMITED
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 ASPEN HOLDINGS
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 AUROBINDO PHARMA USA (SUBSIDIARY OF AUROBINDO PHARMA LIMITED)
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 BAUSCH HEALTH COMPANIES INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 BIOCON.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENTS
17.14 CIPLA
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 EMCURE PHARMACEUTICALS LIMITED
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 ENDO, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 FRESENIUS SE & CO. KGAA
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 GLENMARK PHARMACEUTICALS LTD.
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 HIKMA PHARMACEUTICALS PLC
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.2 INTAS PHARMACEUTICALS LTD.
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENTS
17.21 JUBILANT GENERICS LIMITED (SUBSIDIARY OF JUBILANT PHARMA COMPANY)
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENTS
17.22 LUPIN
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENTS
17.23 MANKIND PHARMA LIMITED
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENTS
17.24 NATCO PHARMA LIMITED
17.24.1 COMPANY SNAPSHOT
17.24.2 REVENUE ANALYSIS
17.24.3 PRODUCT PORTFOLIO
17.24.4 RECENT DEVELOPMENTS
17.25 NEULAND LABORATORIES LTD.
17.25.1 COMPANY SNAPSHOT
17.25.2 REVENUE ANALYSIS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENT
17.26 ORCHIDPHARMA LTD.
17.26.1 COMPANY SNAPSHOT
17.26.2 REVENUE ANALYSIS
17.26.3 PRODUCT PORTFOLIO
17.26.4 RECENT DEVELOPMENT
17.27 PANACEA BIOTEC
17.27.1 COMPANY SNAPSHOT
17.27.2 REVENUE ANALYSIS
17.27.3 PRODUCT PORTFOLIO
17.27.4 RECENT DEVELOPMENT
17.28 SAGENT
17.28.1 COMPANY SNAPSHOT
17.28.2 PRODUCT PORTFOLIO
17.28.3 RECENT DEVELOPMENT
17.29 STRIDES PHARMA SCIENCE LIMITED.
17.29.1 COMPANY SNAPSHOT
17.29.2 REVENUE ANALYSIS
17.29.3 PRODUCT PORTFOLIO
17.29.4 RECENT DEVELOPMENT
17.3 TORRENT PHARMACEUTICALS LTD.
17.30.1 COMPANY SNAPSHOT
17.30.2 REVENUE ANALYSIS
17.30.3 PRODUCT PORTFOLIO
17.30.4 RECENT DEVELOPMENTS
17.31 USV PRIVATE LIMITED.
17.31.1 COMPANY SNAPSHOT
17.31.2 SERVICE PORTFOLIO
17.31.3 RECENT DEVELOPMENT
17.32 WOCKHARDT LIMITED
17.32.1 COMPANY SNAPSHOT
17.32.2 REVENUE ANALYSIS
17.32.3 PRODUCT PORTFOLIO
17.32.4 RECENT DEVELOPMENT
17.33 MCKESSON CORPORATION
17.33.1 COMPANY SNAPSHOT
17.33.2 REVENUE ANALYSIS
17.33.3 PRODUCT PORTFOLIO
17.33.4 RECENT DEVELOPMENT
17.34 CENCORA, INC.
17.34.1 COMPANY SNAPSHOT
17.34.2 REVENUE ANALYSIS
17.34.3 PRODUCT PORTFOLIO
17.34.4 RECENT DEVELOPMENT
17.35 CARDINAL HEALTH
17.35.1 COMPANY SNAPSHOT
17.35.2 REVENUE ANALYSIS
17.35.3 PRODUCT PORTFOLIO
17.35.4 RECENT DEVELOPMENT
17.36 ALVOGEN
17.36.1 COMPANY SNAPSHOT
17.36.2 SERVICE PORTFOLIO
17.36.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
표 목록
TABLE 1 BRAND COMPARATIVE ANALYSIS OF THE EUROPE BRANDED GENERICS MARKET
TABLE 2 PATENT LANDSCAPE
TABLE 3 EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 4 EUROPE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 EUROPE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 EUROPE DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 EUROPE ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 EUROPE ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 EUROPE BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 10 EUROPE CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 EUROPE DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 EUROPE ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 EUROPE CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 EUROPE HORMONES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 EUROPE HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 EUROPE STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 17 EUROPE SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 18 EUROPE ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 19 EUROPE PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 20 EUROPE ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 EUROPE THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 22 EUROPE OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 23 EUROPE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 EUROPE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 25 EUROPE PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 26 EUROPE PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 27 EUROPE FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 28 EUROPE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 EUROPE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 EUROPE STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 31 EUROPE COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 32 EUROPE FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 33 EUROPE BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 EUROPE PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 EUROPE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 EUROPE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 EUROPE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 EUROPE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 39 EUROPE NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 40 EUROPE NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 EUROPE ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 EUROPE TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 EUROPE ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 44 EUROPE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 EUROPE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 46 EUROPE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 47 EUROPE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 48 EUROPE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 EUROPE ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 EUROPE MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 EUROPE NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 EUROPE ANTI-PSYCHOTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 53 EUROPE ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 EUROPE SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 EUROPE FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 EUROPE PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 57 EUROPE THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 EUROPE NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 59 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 60 EUROPE BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 61 EUROPE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 62 EUROPE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 EUROPE PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 64 EUROPE PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 EUROPE ONCOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 66 EUROPE ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 EUROPE SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 EUROPE HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 EUROPE DIABETES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 70 EUROPE DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 EUROPE NEUROLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 72 EUROPE NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 EUROPE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 74 EUROPE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 EUROPE DERMATOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 76 EUROPE DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 78 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 EUROPE BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 80 EUROPE ORAL IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 81 EUROPE ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 EUROPE INJECTABLE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 83 EUROPE INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 EUROPE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 85 EUROPE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 87 EUROPE BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 EUROPE VALUE-ADDED BRANDED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 89 EUROPE TRADE NAMED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 90 EUROPE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 91 EUROPE ADULT IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 92 EUROPE GERIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 93 EUROPE PEDIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 94 EUROPE BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 95 EUROPE HOSPITALS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 96 EUROPE CLINICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 97 EUROPE HOMECARE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 98 EUROPE ACADEMIC & RESEARCH INSTITUTES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 99 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 100 EUROPE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 101 EUROPE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 102 EUROPE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 EUROPE HOSPITAL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 104 EUROPE DIRECT TENDERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 105 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 106 EUROPE BRANDED GENERICS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 107 EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 108 EUROPE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 EUROPE DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 EUROPE ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 EUROPE ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 EUROPE BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 EUROPE CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 EUROPE DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 EUROPE ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 EUROPE CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 EUROPE HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 EUROPE STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 EUROPE SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 EUROPE ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 EUROPE PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 EUROPE ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 EUROPE THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 124 EUROPE OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 EUROPE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 EUROPE PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 EUROPE PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 EUROPE FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 EUROPE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 EUROPE STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 131 EUROPE COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 EUROPE FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 EUROPE BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 EUROPE PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 EUROPE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 EUROPE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 EUROPE NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 EUROPE NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 EUROPE ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 EUROPE TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 EUROPE ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 EUROPE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 EUROPE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 EUROPE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 EUROPE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 146 EUROPE ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 EUROPE MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 EUROPE NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 149 EUROPE ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 EUROPE SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 EUROPE FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 EUROPE PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 EUROPE THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 EUROPE NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 EUROPE BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 156 EUROPE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 EUROPE PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 EUROPE ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 EUROPE SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 160 EUROPE HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 EUROPE DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 162 EUROPE NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 EUROPE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 EUROPE DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 EUROPE OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 EUROPE BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 167 EUROPE ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 EUROPE INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 EUROPE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 EUROPE BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 EUROPE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 172 EUROPE BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 173 EUROPE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 174 EUROPE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 GERMANY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 176 GERMANY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 GERMANY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 GERMANY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 GERMANY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 180 GERMANY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 GERMANY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 GERMANY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 183 GERMANY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 184 GERMANY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 185 GERMANY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 186 GERMANY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 187 GERMANY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 188 GERMANY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 189 GERMANY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 GERMANY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 GERMANY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 GERMANY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 GERMANY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 GERMANY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 GERMANY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 GERMANY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 GERMANY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 GERMANY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 GERMANY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 GERMANY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 GERMANY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 GERMANY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 203 GERMANY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 204 GERMANY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 GERMANY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 GERMANY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 GERMANY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 GERMANY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 GERMANY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 GERMANY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 GERMANY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 212 GERMANY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 213 GERMANY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 214 GERMANY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 GERMANY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 GERMANY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 GERMANY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 218 GERMANY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 GERMANY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 GERMANY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 221 GERMANY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 GERMANY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 GERMANY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 224 GERMANY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 GERMANY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 GERMANY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 GERMANY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 GERMANY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 GERMANY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 230 GERMANY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 GERMANY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 GERMANY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 233 GERMANY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 234 GERMANY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 235 GERMANY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 236 GERMANY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 GERMANY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 GERMANY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 239 GERMANY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 240 GERMANY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 241 GERMANY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 242 GERMANY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 243 UNITED KINGDOM BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 244 UNITED KINGDOM ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 245 UNITED KINGDOM DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 UNITED KINGDOM ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 UNITED KINGDOM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 248 UNITED KINGDOM BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 249 UNITED KINGDOM CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 250 UNITED KINGDOM DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 251 UNITED KINGDOM ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 252 UNITED KINGDOM CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 UNITED KINGDOM HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 UNITED KINGDOM STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 UNITED KINGDOM SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 UNITED KINGDOM ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 257 UNITED KINGDOM PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 258 UNITED KINGDOM ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 UNITED KINGDOM THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 UNITED KINGDOM OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 UNITED KINGDOM ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 UNITED KINGDOM PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 263 UNITED KINGDOM PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 264 UNITED KINGDOM FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 265 UNITED KINGDOM LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 266 UNITED KINGDOM STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 UNITED KINGDOM COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 UNITED KINGDOM FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 UNITED KINGDOM BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 270 UNITED KINGDOM PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 271 UNITED KINGDOM ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 272 UNITED KINGDOM ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 UNITED KINGDOM NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 274 UNITED KINGDOM NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 UNITED KINGDOM ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 UNITED KINGDOM TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 UNITED KINGDOM ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 278 UNITED KINGDOM ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 UNITED KINGDOM SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 280 UNITED KINGDOM SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 281 UNITED KINGDOM TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 UNITED KINGDOM ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 283 UNITED KINGDOM MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 284 UNITED KINGDOM NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 285 UNITED KINGDOM ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 286 UNITED KINGDOM SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 UNITED KINGDOM FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 288 UNITED KINGDOM PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 289 UNITED KINGDOM THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 UNITED KINGDOM NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 291 UNITED KINGDOM BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 292 UNITED KINGDOM CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 UNITED KINGDOM PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 UNITED KINGDOM ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 295 UNITED KINGDOM SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 UNITED KINGDOM HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 297 UNITED KINGDOM DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 UNITED KINGDOM NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 UNITED KINGDOM GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 UNITED KINGDOM DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 301 UNITED KINGDOM OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 UNITED KINGDOM BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 303 UNITED KINGDOM ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 UNITED KINGDOM INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 UNITED KINGDOM TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 UNITED KINGDOM BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 307 UNITED KINGDOM BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 308 UNITED KINGDOM BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 309 UNITED KINGDOM BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 310 UNITED KINGDOM RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 ITALY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 312 ITALY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 313 ITALY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 314 ITALY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 315 ITALY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 316 ITALY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 317 ITALY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 318 ITALY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 319 ITALY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 ITALY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 321 ITALY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 322 ITALY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 323 ITALY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 ITALY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 ITALY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 326 ITALY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 ITALY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 328 ITALY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 329 ITALY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 330 ITALY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 331 ITALY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 332 ITALY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 333 ITALY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 334 ITALY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 335 ITALY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 336 ITALY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 337 ITALY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 338 ITALY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 339 ITALY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 340 ITALY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 341 ITALY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 342 ITALY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 343 ITALY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 344 ITALY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 345 ITALY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 ITALY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 347 ITALY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 348 ITALY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 349 ITALY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 350 ITALY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 ITALY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 ITALY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 353 ITALY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 ITALY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 ITALY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 ITALY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 ITALY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 358 ITALY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 359 ITALY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 360 ITALY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 361 ITALY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 362 ITALY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 363 ITALY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 364 ITALY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 365 ITALY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 366 ITALY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 367 ITALY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 368 ITALY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 369 ITALY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 370 ITALY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 371 ITALY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 372 ITALY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 373 ITALY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 374 ITALY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 375 ITALY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 376 ITALY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 377 ITALY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 378 ITALY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 379 FRANCE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 380 FRANCE ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 381 FRANCE DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 382 FRANCE ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 383 FRANCE ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 384 FRANCE BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 385 FRANCE CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 386 FRANCE DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 FRANCE ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 388 FRANCE CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 389 FRANCE HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 390 FRANCE STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 391 FRANCE SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 392 FRANCE ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 393 FRANCE PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 394 FRANCE ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 395 FRANCE THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 396 FRANCE OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 397 FRANCE ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 398 FRANCE PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 399 FRANCE PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 400 FRANCE FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 401 FRANCE LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 402 FRANCE STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 403 FRANCE COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 404 FRANCE FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 405 FRANCE BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 406 FRANCE PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 407 FRANCE ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 FRANCE ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 FRANCE NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 410 FRANCE NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 411 FRANCE ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 FRANCE TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 413 FRANCE ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 414 FRANCE ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 415 FRANCE SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 FRANCE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 FRANCE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 418 FRANCE ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 419 FRANCE MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 420 FRANCE NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 421 FRANCE ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 422 FRANCE SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 423 FRANCE FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 424 FRANCE PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 FRANCE THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 FRANCE NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 427 FRANCE BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 428 FRANCE CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 429 FRANCE PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 430 FRANCE ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 431 FRANCE SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 432 FRANCE HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 433 FRANCE DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 434 FRANCE NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 435 FRANCE GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 436 FRANCE DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 FRANCE OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 438 FRANCE BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 439 FRANCE ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 440 FRANCE INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 441 FRANCE TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 442 FRANCE BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 443 FRANCE BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 444 FRANCE BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 445 FRANCE BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 446 FRANCE RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 447 SPAIN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 448 SPAIN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 449 SPAIN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 450 SPAIN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 451 SPAIN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 SPAIN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 453 SPAIN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 454 SPAIN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 455 SPAIN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 456 SPAIN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 SPAIN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 458 SPAIN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 459 SPAIN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 460 SPAIN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 461 SPAIN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 462 SPAIN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 463 SPAIN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 464 SPAIN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 465 SPAIN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 466 SPAIN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 467 SPAIN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 468 SPAIN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 469 SPAIN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 470 SPAIN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 471 SPAIN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 472 SPAIN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 473 SPAIN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 474 SPAIN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 475 SPAIN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 476 SPAIN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 477 SPAIN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 478 SPAIN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 479 SPAIN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 480 SPAIN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 481 SPAIN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 SPAIN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 483 SPAIN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 484 SPAIN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 485 SPAIN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 486 SPAIN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 487 SPAIN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 488 SPAIN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 489 SPAIN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 490 SPAIN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 491 SPAIN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 492 SPAIN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 493 SPAIN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 494 SPAIN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 495 SPAIN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 496 SPAIN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 497 SPAIN PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 498 SPAIN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 499 SPAIN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 500 SPAIN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 501 SPAIN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 502 SPAIN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 503 SPAIN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 SPAIN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 505 SPAIN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 506 SPAIN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 507 SPAIN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 508 SPAIN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 SPAIN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 510 SPAIN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 511 SPAIN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 512 SPAIN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 513 SPAIN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 514 SPAIN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 515 TURKEY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 516 TURKEY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 517 TURKEY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 518 TURKEY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 519 TURKEY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 520 TURKEY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 521 TURKEY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 522 TURKEY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 523 TURKEY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 524 TURKEY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 525 TURKEY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 526 TURKEY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 527 TURKEY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 528 TURKEY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 529 TURKEY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 530 TURKEY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 531 TURKEY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 532 TURKEY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 533 TURKEY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 534 TURKEY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 535 TURKEY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 536 TURKEY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 537 TURKEY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 538 TURKEY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 539 TURKEY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 540 TURKEY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 541 TURKEY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 542 TURKEY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 543 TURKEY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 544 TURKEY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 545 TURKEY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 546 TURKEY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 547 TURKEY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 548 TURKEY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 549 TURKEY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 550 TURKEY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 551 TURKEY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 552 TURKEY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 553 TURKEY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 554 TURKEY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 555 TURKEY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 556 TURKEY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 557 TURKEY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 558 TURKEY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 559 TURKEY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 560 TURKEY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 561 TURKEY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 562 TURKEY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 563 TURKEY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 564 TURKEY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 565 TURKEY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 566 TURKEY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 567 TURKEY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 568 TURKEY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 569 TURKEY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 570 TURKEY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 571 TURKEY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 572 TURKEY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 573 TURKEY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 574 TURKEY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 575 TURKEY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 576 TURKEY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 577 TURKEY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 578 TURKEY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 579 TURKEY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 580 TURKEY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 581 TURKEY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 582 TURKEY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 583 RUSSIA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 584 RUSSIA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 585 RUSSIA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 586 RUSSIA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 587 RUSSIA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 588 RUSSIA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 589 RUSSIA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 590 RUSSIA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 591 RUSSIA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 592 RUSSIA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 593 RUSSIA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 594 RUSSIA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 595 RUSSIA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 596 RUSSIA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 597 RUSSIA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 598 RUSSIA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 599 RUSSIA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 600 RUSSIA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 601 RUSSIA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 602 RUSSIA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 603 RUSSIA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 604 RUSSIA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 605 RUSSIA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 606 RUSSIA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 607 RUSSIA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 608 RUSSIA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 609 RUSSIA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 610 RUSSIA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 611 RUSSIA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 612 RUSSIA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 613 RUSSIA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 614 RUSSIA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 615 RUSSIA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 616 RUSSIA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 617 RUSSIA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 618 RUSSIA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 619 RUSSIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 620 RUSSIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 621 RUSSIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 622 RUSSIA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 623 RUSSIA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 624 RUSSIA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 625 RUSSIA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 626 RUSSIA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 627 RUSSIA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 628 RUSSIA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 629 RUSSIA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 630 RUSSIA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 631 RUSSIA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 632 RUSSIA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 633 RUSSIA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 634 RUSSIA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 635 RUSSIA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 636 RUSSIA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 637 RUSSIA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 638 RUSSIA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 639 RUSSIA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 640 RUSSIA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 641 RUSSIA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 642 RUSSIA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 643 RUSSIA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 644 RUSSIA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 645 RUSSIA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 646 RUSSIA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 647 RUSSIA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 648 RUSSIA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 649 RUSSIA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 650 RUSSIA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 651 SWITZERLAND BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 652 SWITZERLAND ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 653 SWITZERLAND DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 654 SWITZERLAND ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 655 SWITZERLAND ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 656 SWITZERLAND BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 657 SWITZERLAND CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 658 SWITZERLAND DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 659 SWITZERLAND ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 660 SWITZERLAND CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 661 SWITZERLAND HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 662 SWITZERLAND STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 663 SWITZERLAND SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 664 SWITZERLAND ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 665 SWITZERLAND PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 666 SWITZERLAND ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 667 SWITZERLAND THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 668 SWITZERLAND OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 669 SWITZERLAND ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 670 SWITZERLAND PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 671 SWITZERLAND PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 672 SWITZERLAND FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 673 SWITZERLAND LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 674 SWITZERLAND STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 675 SWITZERLAND COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 676 SWITZERLAND FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 677 SWITZERLAND BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 678 SWITZERLAND PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 679 SWITZERLAND ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 680 SWITZERLAND ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 681 SWITZERLAND NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 682 SWITZERLAND NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 683 SWITZERLAND ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 684 SWITZERLAND TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 685 SWITZERLAND ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 686 SWITZERLAND ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 687 SWITZERLAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 688 SWITZERLAND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 689 SWITZERLAND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 690 SWITZERLAND ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 691 SWITZERLAND MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 692 SWITZERLAND NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 693 SWITZERLAND ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 694 SWITZERLAND SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 695 SWITZERLAND FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 696 SWITZERLAND PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 697 SWITZERLAND THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 698 SWITZERLAND NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 699 SWITZERLAND BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 700 SWITZERLAND CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 701 SWITZERLAND PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 702 SWITZERLAND ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 703 SWITZERLAND SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 704 SWITZERLAND HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 705 SWITZERLAND DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 706 SWITZERLAND NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 707 SWITZERLAND GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 708 SWITZERLAND DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 709 SWITZERLAND OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 710 SWITZERLAND BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 711 SWITZERLAND ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 712 SWITZERLAND INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 713 SWITZERLAND TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 714 SWITZERLAND BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 715 SWITZERLAND BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 716 SWITZERLAND BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 717 SWITZERLAND BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 718 SWITZERLAND RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 719 NETHERLANDS BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 720 NETHERLANDS ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 721 NETHERLANDS DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 722 NETHERLANDS ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 723 NETHERLANDS ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 724 NETHERLANDS BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 725 NETHERLANDS CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 726 NETHERLANDS DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 727 NETHERLANDS ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 728 NETHERLANDS CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 729 NETHERLANDS HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 730 NETHERLANDS STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 731 NETHERLANDS SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 732 NETHERLANDS ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 733 NETHERLANDS PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 734 NETHERLANDS ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 735 NETHERLANDS THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 736 NETHERLANDS OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 737 NETHERLANDS ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 738 NETHERLANDS PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 739 NETHERLANDS PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 740 NETHERLANDS FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 741 NETHERLANDS LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 742 NETHERLANDS STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 743 NETHERLANDS COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 744 NETHERLANDS FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 745 NETHERLANDS BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 746 NETHERLANDS PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 747 NETHERLANDS ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 748 NETHERLANDS ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 749 NETHERLANDS NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 750 NETHERLANDS NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 751 NETHERLANDS ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 752 NETHERLANDS TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 753 NETHERLANDS ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 754 NETHERLANDS ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 755 NETHERLANDS SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 756 NETHERLANDS SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 757 NETHERLANDS TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 758 NETHERLANDS ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 759 NETHERLANDS MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 760 NETHERLANDS NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 761 NETHERLANDS ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 762 NETHERLANDS SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 763 NETHERLANDS FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 764 NETHERLANDS PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 765 NETHERLANDS THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 766 NETHERLANDS NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 767 NETHERLANDS BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 768 NETHERLANDS CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 769 NETHERLANDS PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 770 NETHERLANDS ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 771 NETHERLANDS SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 772 NETHERLANDS HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 773 NETHERLANDS DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 774 NETHERLANDS NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 775 NETHERLANDS GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 776 NETHERLANDS DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 777 NETHERLANDS OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 778 NETHERLANDS BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 779 NETHERLANDS ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 780 NETHERLANDS INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 781 NETHERLANDS TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 782 NETHERLANDS BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 783 NETHERLANDS BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 784 NETHERLANDS BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 785 NETHERLANDS BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 786 NETHERLANDS RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 787 BELGIUM BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 788 BELGIUM ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 789 BELGIUM DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 790 BELGIUM ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 791 BELGIUM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 792 BELGIUM BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 793 BELGIUM CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 794 BELGIUM DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 795 BELGIUM ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 796 BELGIUM CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 797 BELGIUM HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 798 BELGIUM STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 799 BELGIUM SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 800 BELGIUM ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 801 BELGIUM PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 802 BELGIUM ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 803 BELGIUM THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 804 BELGIUM OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 805 BELGIUM ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 806 BELGIUM PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 807 BELGIUM PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 808 BELGIUM FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 809 BELGIUM LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 810 BELGIUM STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 811 BELGIUM COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 812 BELGIUM FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 813 BELGIUM BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 814 BELGIUM PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 815 BELGIUM ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 816 BELGIUM ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 817 BELGIUM NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 818 BELGIUM NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 819 BELGIUM ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 820 BELGIUM TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 821 BELGIUM ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 822 BELGIUM ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 823 BELGIUM SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 824 BELGIUM SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 825 BELGIUM TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 826 BELGIUM ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 827 BELGIUM MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 828 BELGIUM NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 829 BELGIUM ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 830 BELGIUM SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 831 BELGIUM FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 832 BELGIUM PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 833 BELGIUM THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 834 BELGIUM NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 835 BELGIUM BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 836 BELGIUM CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 837 BELGIUM PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 838 BELGIUM ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 839 BELGIUM SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 840 BELGIUM HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 841 BELGIUM DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 842 BELGIUM NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 843 BELGIUM GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 844 BELGIUM DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 845 BELGIUM OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 846 BELGIUM BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 847 BELGIUM ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 848 BELGIUM INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 849 BELGIUM TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 850 BELGIUM BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 851 BELGIUM BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 852 BELGIUM BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 853 BELGIUM BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 854 BELGIUM RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 855 SWEDEN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 856 SWEDEN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 857 SWEDEN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 858 SWEDEN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 859 SWEDEN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 860 SWEDEN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 861 SWEDEN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 862 SWEDEN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 863 SWEDEN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 864 SWEDEN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 865 SWEDEN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 866 SWEDEN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 867 SWEDEN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 868 SWEDEN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 869 SWEDEN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 870 SWEDEN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 871 SWEDEN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 872 SWEDEN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 873 SWEDEN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 874 SWEDEN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 875 SWEDEN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 876 SWEDEN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 877 SWEDEN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 878 SWEDEN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 879 SWEDEN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 880 SWEDEN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 881 SWEDEN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 882 SWEDEN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 883 SWEDEN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 884 SWEDEN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 885 SWEDEN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 886 SWEDEN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 887 SWEDEN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 888 SWEDEN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 889 SWEDEN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 890 SWEDEN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 891 SWEDEN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 892 SWEDEN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 893 SWEDEN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 894 SWEDEN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 895 SWEDEN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 896 SWEDEN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 897 SWEDEN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 898 SWEDEN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 899 SWEDEN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 900 SWEDEN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 901 SWEDEN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 902 SWEDEN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 903 SWEDEN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 904 SWEDEN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 905 SWEDEN PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 906 SWEDEN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 907 SWEDEN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 908 SWEDEN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 909 SWEDEN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 910 SWEDEN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 911 SWEDEN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 912 SWEDEN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 913 SWEDEN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 914 SWEDEN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 915 SWEDEN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 916 SWEDEN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 917 SWEDEN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 918 SWEDEN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 919 SWEDEN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 920 SWEDEN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 921 SWEDEN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 922 SWEDEN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 923 DENMARK BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 924 DENMARK ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 925 DENMARK DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 926 DENMARK ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 927 DENMARK ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 928 DENMARK BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 929 DENMARK CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 930 DENMARK DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 931 DENMARK ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 932 DENMARK CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 933 DENMARK HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 934 DENMARK STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 935 DENMARK SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 936 DENMARK ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 937 DENMARK PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 938 DENMARK ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 939 DENMARK THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 940 DENMARK OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 941 DENMARK ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 942 DENMARK PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 943 DENMARK PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 944 DENMARK FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 945 DENMARK LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 946 DENMARK STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 947 DENMARK COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 948 DENMARK FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 949 DENMARK BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 950 DENMARK PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 951 DENMARK ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 952 DENMARK ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 953 DENMARK NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 954 DENMARK NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 955 DENMARK ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 956 DENMARK TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 957 DENMARK ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 958 DENMARK ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 959 DENMARK SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 960 DENMARK SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 961 DENMARK TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 962 DENMARK ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 963 DENMARK MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 964 DENMARK NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 965 DENMARK ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 966 DENMARK SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 967 DENMARK FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 968 DENMARK PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 969 DENMARK THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 970 DENMARK NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 971 DENMARK BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 972 DENMARK CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 973 DENMARK PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 974 DENMARK ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 975 DENMARK SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 976 DENMARK HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 977 DENMARK DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 978 DENMARK NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 979 DENMARK GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 980 DENMARK DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 981 DENMARK OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 982 DENMARK BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 983 DENMARK ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 984 DENMARK INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 985 DENMARK TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 986 DENMARK BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 987 DENMARK BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 988 DENMARK BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 989 DENMARK BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 990 DENMARK RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 991 NORWAY BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 992 NORWAY ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 993 NORWAY DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 994 NORWAY ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 995 NORWAY ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 996 NORWAY BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 997 NORWAY CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 998 NORWAY DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 999 NORWAY ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1000 NORWAY CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1001 NORWAY HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1002 NORWAY STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1003 NORWAY SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1004 NORWAY ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1005 NORWAY PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1006 NORWAY ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1007 NORWAY THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1008 NORWAY OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1009 NORWAY ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1010 NORWAY PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1011 NORWAY PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1012 NORWAY FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1013 NORWAY LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1014 NORWAY STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1015 NORWAY COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1016 NORWAY FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1017 NORWAY BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1018 NORWAY PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1019 NORWAY ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1020 NORWAY ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1021 NORWAY NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1022 NORWAY NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1023 NORWAY ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1024 NORWAY TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1025 NORWAY ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1026 NORWAY ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1027 NORWAY SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1028 NORWAY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1029 NORWAY TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1030 NORWAY ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1031 NORWAY MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1032 NORWAY NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1033 NORWAY ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1034 NORWAY SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1035 NORWAY FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1036 NORWAY PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1037 NORWAY THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1038 NORWAY NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1039 NORWAY BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 1040 NORWAY CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1041 NORWAY PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1042 NORWAY ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1043 NORWAY SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1044 NORWAY HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1045 NORWAY DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1046 NORWAY NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1047 NORWAY GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1048 NORWAY DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1049 NORWAY OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1050 NORWAY BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1051 NORWAY ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1052 NORWAY INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1053 NORWAY TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1054 NORWAY BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1055 NORWAY BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 1056 NORWAY BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1057 NORWAY BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1058 NORWAY RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1059 FINLAND BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 1060 FINLAND ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1061 FINLAND DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1062 FINLAND ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1063 FINLAND ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1064 FINLAND BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1065 FINLAND CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1066 FINLAND DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1067 FINLAND ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1068 FINLAND CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1069 FINLAND HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1070 FINLAND STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1071 FINLAND SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1072 FINLAND ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1073 FINLAND PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1074 FINLAND ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1075 FINLAND THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1076 FINLAND OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1077 FINLAND ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1078 FINLAND PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1079 FINLAND PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1080 FINLAND FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1081 FINLAND LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1082 FINLAND STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1083 FINLAND COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1084 FINLAND FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1085 FINLAND BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1086 FINLAND PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1087 FINLAND ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1088 FINLAND ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1089 FINLAND NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1090 FINLAND NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1091 FINLAND ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1092 FINLAND TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1093 FINLAND ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1094 FINLAND ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1095 FINLAND SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1096 FINLAND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1097 FINLAND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1098 FINLAND ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1099 FINLAND MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1100 FINLAND NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1101 FINLAND ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1102 FINLAND SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1103 FINLAND FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1104 FINLAND PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1105 FINLAND THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1106 FINLAND NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1107 FINLAND BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 1108 FINLAND CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1109 FINLAND PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1110 FINLAND ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1111 FINLAND SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1112 FINLAND HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1113 FINLAND DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1114 FINLAND NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1115 FINLAND GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1116 FINLAND DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1117 FINLAND OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1118 FINLAND BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 1119 FINLAND ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1120 FINLAND INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1121 FINLAND TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1122 FINLAND BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 1123 FINLAND BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 1124 FINLAND BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 1125 FINLAND BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 1126 FINLAND RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 1127 REST OF EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
그림 목록
FIGURE 1 EUROPE BRANDED GENERICS MARKET: SEGMENTATION
FIGURE 2 EUROPE BRANDED GENERICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE BRANDED GENERICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE BRANDED GENERICS MARKET: EUROPE VS REGIONAL ANALYSIS
FIGURE 5 EUROPE BRANDED GENERICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE BRANDED GENERICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE BRANDED GENERICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE BRANDED GENERICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EXECUTIVE SUMMARY
FIGURE 10 STRATEGIC DECISIONS
FIGURE 11 NINE SEGMENTS COMPRISE THE EUROPE BRANDED GENERICS MARKET, BY DRUG CLASS (2024)
FIGURE 12 EUROPE BRANDED GENERICS MARKET: SEGMENTATION
FIGURE 13 PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS ARE EXPECTED TO DRIVE THE EUROPE BRANDED GENERICS MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 ANTI-HYPERTENSIVE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BRANDED GENERICS MARKET IN 2025 & 2032
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE EUROPE BRANDED GENERICS MARKET
FIGURE 16 EUROPE BRANDED GENERIC MARKET: BY DRUG CLASS, 2024
FIGURE 17 EUROPE BRANDED GENERIC MARKET: BY DRUG CLASS, 2025 TO 2032 (USD THOUSAND)
FIGURE 18 EUROPE BRANDED GENERIC MARKET: BY DRUG CLASS, CAGR (2025- 2032)
FIGURE 19 EUROPE BRANDED GENERIC MARKET: BY DRUG CLASS, LIFELINE CURVE
FIGURE 20 EUROPE BRANDED GENERICS MARKET: BY APPLICATION, 2024
FIGURE 21 EUROPE BRANDED GENERICS MARKET: BY APPLICATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 22 EUROPE BRANDED GENERICS MARKET: BY APPLICATION, CAGR (2025- 2032)
FIGURE 23 EUROPE BRANDED GENERICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 EUROPE BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2024
FIGURE 25 EUROPE BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 26 EUROPE BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025- 2032)
FIGURE 27 EUROPE BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 EUROPE BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2024
FIGURE 29 EUROPE BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 30 EUROPE BRANDED GENERICS MARKET: BY PRODUCT TYPE, CAGR (2025- 2032)
FIGURE 31 EUROPE BRANDED GENERICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 32 EUROPE BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2024
FIGURE 33 EUROPE BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2025 TO 2032 (USD THOUSAND)
FIGURE 34 EUROPE BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2025- 2032)
FIGURE 35 EUROPE BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE
FIGURE 36 EUROPE BRANDED GENERICS MARKET: BY END USER, 2024
FIGURE 37 EUROPE BRANDED GENERICS MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)
FIGURE 38 EUROPE BRANDED GENERICS MARKET: BY END USER, CAGR (2025- 2032)
FIGURE 39 EUROPE BRANDED GENERICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 EUROPE BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 41 EUROPE BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)
FIGURE 42 EUROPE BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)
FIGURE 43 EUROPE BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 EUROPE BRANDED GENERICS MARKET: SNAPSHOT (2024)
FIGURE 45 EUROPE BRANDED GENERICS MARKET: COMPANY SHARE 2024 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
